Trinity Biotech announces clinical trial results for redesigned CGM sensor

Trinity Biotech (TRIB) announced clinical trial results demonstrating a major technical breakthrough and de-risking the commercial pathway for its next-generation continuous glucose monitoring technology, called CGM+. For the first time, trial data confirms that Trinity Biotech’s redesigned proprietary needle-free glucose sensor delivers accurate glucose readings across a full 15-day wear period without the need for finger-stick calibration, while also facilitating an innovative CGM design that reduces disposable components, significantly lowering the cost of care compared to current leading market products. As the high cost of existing CGM devices continues to hinder widespread adoption, Trinity Biotech’s innovative approach is designed to enhance accessibility and increase utilization of CGM technology.New Trial Data Confirms: No finger-stick calibration required over a 15-day sensor wear period. Enhanced user convenience, comfort, and reliability through proprietary glucose sensor improvements. Successful technical de-risking which increases confidence in next-gen product performance and regulatory pathway. The clinical validation of the calibration-free sensor marks a critical step toward commercialization of Trinity Biotech’s next-generation CGM+ platform. The glucose sensor tested in this trial is integral to the Company’s modular CGM+ device, which is in the later stages of development, with a focus on scalability, cost-efficiency, and environmental impact – key factors that support broader market access and long-term adoption.